Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

884.54
+24.812.89%
Post-market: 886.011.47+0.17%18:35 EDT
Volume:3.40M
Turnover:2.97B
Market Cap:838.53B
PE:75.54
High:885.58
Open:859.66
Low:851.07
Close:859.73
Loading ...

Lilly sues two compounders over copies of weight-loss drugs

Reuters
·
01 Apr

BRIEF-Lilly Sues Two Firms For Selling Unapproved Products Claiming To Contain Tirzepatide

Reuters
·
01 Apr

Eli Lilly Sues Strive Pharmacy Llc, Empower Clinic Services Llc for Selling Unapproved Products Claiming to Contain Tirzepatide

THOMSON REUTERS
·
01 Apr

Eli Lilly: to Send About 50 Cease and Desist Letters to Compounders and Telehealth Firms Asking to Confirm They Have Ceased Mass Compounding

THOMSON REUTERS
·
01 Apr

Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know

Zacks
·
01 Apr

Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip

Simply Wall St.
·
01 Apr

Is the Future Bleak for SAVA Stock Following Another Setback?

Zacks
·
31 Mar

Pharma Stocks Sink After Ouster of Top FDA Vaccine Regulator

Reuters
·
31 Mar

Alphabet's Isomorphic Labs Unit Raises $600 Million for AI-Based Drug Development

MT Newswires Live
·
31 Mar

Noom- Announced Agreement With Eli Lilly & Company's Lillydirect Pharmacy Provider, Gifthealth

THOMSON REUTERS
·
31 Mar

Palatin Technologies Inc - Ind Applications Planned for 4Q25, Clinical Data Expected 1H26

THOMSON REUTERS
·
31 Mar

Palatin Announces Mc4r Agonist Bremelanotide Co-Administered With Glp-1/Gip Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

THOMSON REUTERS
·
31 Mar

Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint

Dow Jones
·
31 Mar

Lilly's Lepodisiran Reduced Levels of Genetically Inherited Heart Disease Risk Factor, Lipoprotein(a), by Nearly 94% From Baseline at the Highest Tested Dose in Adults With Elevated Levels

THOMSON REUTERS
·
31 Mar

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels

PR Newswire
·
31 Mar

Go Big on Defense. It's What Has Worked for Investors Three Months Into 2025. -- Barrons.com

Dow Jones
·
30 Mar

Eli Lilly and Company (LLY): Among Billionaire Ken Fisher’s Top Growth Stock Picks

Insider Monkey
·
29 Mar

Eli Lilly’s (LLY) Alzheimer’s Drug Is Rejected in Europe Over Safety Fears

TIPRANKS
·
29 Mar

CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update

Dow Jones
·
28 Mar

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

Associated Press Finance
·
28 Mar